Publish or Perish - Creating Value through Publications
Publish or Perish - Creating Value through Publications
Johnson & Johnson Innovation, JLABS , 329 Oyster Point Blvd , South San Francisco , CA
January 19, 2017 from 16:30 PM to 20:00 PM (PDT)
$10 - $35
In order to succeed, biotech, drug, and device companies must publish their results in peer-reviewed journals in an effort to add value to promote and commercialize their technologies. The drivers of this exercise include reimbursement, credibility, commercialization and valuations. If you’re not publishing, you’re missing out on valuable opportunities to improve the chances for your company to succeed.
In this interactive program, you will learn the how, why and when of a successful publication strategy. Experts in the field will be joined by professionals who have effectively implemented the process. You will learn from their successes and failures.
Topics to be covered:
- When, where and what to publish
- Timing of publications throughout the product development cycle
- Article types to consider, and why; look at both home runs and base hits
- How peer-reviewed publications support reimbursement strategy
- Developing a roadmap to maximize publication objectives
- PR and your publication program
The program will include case examples and a sample roadmap for success.
Kurt Burgess | Founder, Clinical Alliance Group read bio»
Heidi Chokeir, Ph.D. | Sr. Vice President, Canale Communications read bio»
Douglas Muchmore, MD | Regulatory Affairs, Kinexum read bio»
Tom Michal | Worldwide VP Market Access, Health Economics, Reimbursement, ReWalk Robotics, Inc. read bio»
Kim Martin, Ph.D. | Director of Strategic Research, Zimmer Biomet read bio»
3:30 PM | Registration and Networking
4:00 PM | Presentations and Q&A
5:00 PM | Panel Discussion and Q&A
5:45 PM | Food and Networking
7:00 PM | Program Close
$25 | General Public
$15 | Student/Academic
$45 | At the door
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Kurt Burgess | Founder, Clinical Alliance Group
Kurt Burgess, is a seasoned business development specialist with over 20 years of experience in driving business initiatives for small, mid-cap and enterprise corporations.
Kurt is the founder of the Clinical Alliance Group, a boutique biomedical consulting firm located in Pasadena.
Kurt’s work history includes key senior management positions with CAS Systems (acquired), Rainmaker Systems, and Hilton Hotels. His entrepreneurial experience includes independent consulting with the San Francisco Police Academy, a role as Executive Producer working with Grammy award-winning recording artists, and managing partner in a sports sponsorship effort for emerging junior elite athletes. Much of his free time is spent as a Montana Ambassador, working directly with Governor Bullock’s Office of Business and Economic Development. His Ambassador work has developed key strategic relationships uncovering synergistic economic development opportunities between CA-based corporations and the state of Montana; these relationships led to the launch of Injection Technologies, a medical device start-up currently considering strategic collaborations with a number of southern California based device firms.
Connect with Kurt:
Heidi Chokeir Ph.D. | Senior Vice President, Canale Communications
Heidi Chokeir, Ph.D., is senior vice president at Canale Communications, a life science communications agency in San Diego. In addition to serving as a senior strategy lead, Heidi is CanaleComm’s unofficial chief scientific officer—always ready to dive deep into the science that makes each client unique.
Since joining CanaleComm in 2011, Heidi has put to use her background in science, innate storytelling skills and strategic thinking for clients ranging from the smallest of venture-backed biotech startups to the largest healthcare company in the world. She’s passionate about simplifying scientifically complex stories into messages that are compelling for audiences important to life science companies, including investors, potential partners and patients.
Heidi has planned and implemented award-winning public relations campaigns resulting in media coverage by outlets such as The New York Times, The Wall Street Journal, Bloomberg News, Fortune, IN VIVO, BioCentury, BioWorld Today and Biotech Nation. Prior to CanaleComm, Heidi served as account supervisor at Russo Partners, working primarily with early-stage biotech companies and research institutions.
She holds a Bachelor of Science in biochemistry with a minor in mathematics from Mount Saint Mary’s College in Los Angeles, and a Ph.D. in macromolecular and cellular structure and chemistry from The Scripps Research Institute in San Diego.
Connect with Heidi:
Douglas Muchmore, MD | Regulatory Affairs, Kinexum
Douglas has over 20 years of drug development and regulatory affairs experience in the pharmaceutical and biotech industry, with experience at Eli Lilly and Halozyme Therapeutics. He has authored over 50 peer-reviewed publications in biochemistry, diabetes, osteoporosis and breast cancer. Douglas has 13+ years in teriary care Endocrinology and Metabolism medical practice. He was program director of Endocrinology and Metabolism training fellowship at Scripps Clinic and Research Foundation, La Jolla, CA. Douglas completed his medical training and laboratory research at the University of California, San Diego and has an AB in Biology from Stanford University.
Connect with Douglas:
Tom Michal | Worldwide VP of Market Access, Health Economics & Reimbursement, ReWalk Robotics, Inc.
Tom has over 2 decades of healthcare experience with emphasis on market assessment, health economics, global reimbursement and government relations. He is a recognized expert in coding, coverage, and payment initiatives in start-up environments, as well as enterprise-level biomedical firms. As a specialist in market access and early commercialization, Tom has been responsible for guiding company efforts in key global markets in an effort to drive innovative technology adoption. Tom has developed numerous publication planning and presentation strategies in an effort to create the appropriate “messaging” that supports product claims and long term commercialization objectives.
Connect with Tom:
Kim Martin, Ph.D. | Director of Strategic Research, Zimmer Biomet
Kim has 20 years of experience in basic science, pharmaceutical and medical device clinical research, medical writing, and regulatory strategy. She has broad knowledge of experimental, preclinical, and clinical trial design toward FDA and/or payer approval. Kim haswell-established writing, statistical, and clinical analytical skills demonstrated by first author publications in reputable peer reviewed journals, as well as multiple successful efforts for FDA clearance, CE mark, and for private payer coding payment based on clinical evidence analysis. She has led medical science teams for experimentation required for regulatory clearance for major indications changes based on clinical data and experimental supporting evidence in multiple therapeutic areas including spine, thoracic, cardiovascular, ENT, Radiofrequency ablation, and oncology at a major medical device firms.
Connect with Kim: